Cargando…

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotta, Katsuyuki, Fujimoto, Nobukazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057421/
https://www.ncbi.nlm.nih.gov/pubmed/32098830
http://dx.doi.org/10.1136/jitc-2019-000461
_version_ 1783503653807587328
author Hotta, Katsuyuki
Fujimoto, Nobukazu
author_facet Hotta, Katsuyuki
Fujimoto, Nobukazu
author_sort Hotta, Katsuyuki
collection PubMed
description Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.
format Online
Article
Text
id pubmed-7057421
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70574212020-03-05 Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma Hotta, Katsuyuki Fujimoto, Nobukazu J Immunother Cancer Review Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both first-line and salvage therapies. Specifically, in the Japanese single-arm, phase II trial, the MERIT trial, nivolumab, an antiprogrammed cell death 1 (PD-1) antibody showed favorable efficacy when used as a salvage therapy. Currently, multiple ICI monotherapy or combination therapy trials have been conducted, which could provide further evidence. Among available ICIs, the anti-PD-1 antibody is promising for unresectable MPM, despite the limited efficacy of anti-CTLA4 monotherapy. Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM. BMJ Publishing Group 2020-02-24 /pmc/articles/PMC7057421/ /pubmed/32098830 http://dx.doi.org/10.1136/jitc-2019-000461 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Hotta, Katsuyuki
Fujimoto, Nobukazu
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
title Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
title_full Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
title_fullStr Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
title_full_unstemmed Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
title_short Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
title_sort current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057421/
https://www.ncbi.nlm.nih.gov/pubmed/32098830
http://dx.doi.org/10.1136/jitc-2019-000461
work_keys_str_mv AT hottakatsuyuki currentevidenceandfutureperspectivesofimmunecheckpointinhibitorsinunresectablemalignantpleuralmesothelioma
AT fujimotonobukazu currentevidenceandfutureperspectivesofimmunecheckpointinhibitorsinunresectablemalignantpleuralmesothelioma